These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34046364)

  • 1. Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers.
    Tőke J; Jakab Z; Stark J; Huszty G; Reismann P; Tóth M
    Front Oncol; 2021; 11():680853. PubMed ID: 34046364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
    El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
    Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
    Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Embolism as an Initial Presentation of Adrenocortical Carcinoma.
    Aung SY; Parente P; McKendrick J
    World J Oncol; 2014 Jun; 5(3):149-152. PubMed ID: 29147395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
    Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane.
    Alam W; Bouferraa Y; Haibe Y; Shamseddine A
    Clin Med Insights Oncol; 2021; 15():11795549211007682. PubMed ID: 33889043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
    Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
    Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study.
    Altieri B; Sbiera S; Herterich S; De Francia S; Della Casa S; Calabrese A; Pontecorvi A; Quinkler M; Kienitz T; Mannelli M; Canu L; Angelousi A; Chortis V; Kroiss M; Terzolo M; Fassnacht M; Ronchi CL
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment.
    Libé R
    Front Cell Dev Biol; 2015; 3():45. PubMed ID: 26191527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.
    Vezzosi D; Do Cao C; Hescot S; Bertherat J; Haissaguerre M; Bongard V; Drui D; De La Fouchardière C; Illouz F; Borson-Chazot F; Djobo B; Berdelou A; Tabarin A; Schlumberger M; Briet C; Caron P; Leboulleux S; Libe R; Baudin E;
    Horm Cancer; 2018 Feb; 9(1):62-69. PubMed ID: 29071575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer.
    Head L; Kiseljak-Vassiliades K; Clark TJ; Somerset H; King J; Raeburn C; Albuja-Cruz M; Weyant M; Cleveland J; Wierman ME; Leong S
    J Endocr Soc; 2019 Dec; 3(12):2295-2304. PubMed ID: 31745526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
    Yamashita D; Hanai T; Onuki T; Suzuki K; Nakayama T
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):12-17. PubMed ID: 31956212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
    Seki M; Nomura K; Hirohara D; Kanazawa M; Sawada T; Takasaki K; Demura H
    Endocr Relat Cancer; 1999 Dec; 6(4):529-33. PubMed ID: 10730906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.